Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?

Relay Therapeutics, Inc. (RLAY) shares ended the last trading session 16.4% higher at $12.54. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.1% gain over the past four weeks.

Relay Therapeutics’ share price gain reflects growing investor confidence in the strength of its lead asset, zovegalisib (RLY-2608), a PI3Kα inhibitor, which is advancing into late-stage development with an ongoing phase III breast cancer study (ReDiscover-2). The drug is also being expanded into earlier-line breast cancer settings and non-oncology indications like vascular malformations, with multiple data readouts expected in 2026. The company is also advancing RLY-8161 for Fabry disease, strengthening its genetic disease pipeline. Meanwhile, its FGFR2 inhibitor lirafugratinib (RLY-4008) has been out-licensed to Elevar and already has an NDA filed with the FDA.

This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +23.9%. Revenues are expected to be $15.35 million, up 99.9% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Relay Therapeutics, the consensus EPS estimate for the quarter has been revised 4.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on RLAY going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Relay Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, electroCore, Inc. (ECOR), closed the last trading session 3% higher at $6.8. Over the past month, ECOR has returned -17.2%.

electroCore's consensus EPS estimate for the upcoming report has changed -10.1% over the past month to -$0.59. Compared to the company's year-ago EPS, this represents a change of -25.5%. electroCore currently boasts a Zacks Rank of #3 (Hold).

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

See Top Quantum Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Relay Therapeutics, Inc. (RLAY): Free Stock Analysis Report

electroCore, Inc. (ECOR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research